La semaglutida frente a sitagliptina, en combinacin con 12 medicamentos hipoglucemiantes orales (MHO): metformina y/o tiazolidinedionas El tratamiento con semaglutida en dosis de 0.5 mg y 1 mg una vez a la semana durante 56 semanas en comparacin con sitagliptina result en una reduccin sostenible y estadsticamente ms significativa de los valores de HbA1c (-1.3%, -1.6% frente a -0.5%, respectivamente), GPA (-2.1 mmol/L, -2.6 mmol/L frente a -1.1 mmol/L, respectivamente) y peso corporal (-4.3 kg, -6.1 kg frente a -1.9 kg, respectivamente)
Article | July 24, 2025 Trimming time: metabolomics insights to speed development of GLP-1 therapies Multiple GLP-1-based therapies for type 2 diabetes and obesity have been approved in recent years, reflecting their strong clinical effectiveness in improving glycemic control
And this, sometimes you gotta do protein powders
[5] Patients should be advised to maintain hydration and inform their provider if severe vomiting or diarrhea occurs, as that could affect drug absorption or lead to dehydration
We don't have data on people using BPC-157 for years
The INR - or other appropriate coagulation tests - should be checked weekly until the values stabilize and then monthly, in patients taking anticoagulants together with the drug
)
)
